This page is an index, not a verdict. For each goal below it names the compound in this library with the most rigorous evidence behind it, states plainly what kind of evidence that is, and links to the full guide and to each compound's own page. Nothing here is a dose recommendation or a promise about what will happen to you. It is a summary of what has actually been published.
How the ranking works
Every goal guide on this site uses the same order of evidence, from strongest to weakest: an approved drug or a human randomised controlled trial, then a small human pilot study, then animal data, then cell-culture or mechanism-only findings. A compound that is heavily marketed but never tested for a given goal does not appear near the top just because it sells well. Where the honest answer is "animal data only" or "no human trial found", that is what the linked guide says.
The goals covered so far
| Goal | Strongest-evidenced compound here | What that evidence is |
|---|---|---|
| Injury and tissue healing | BPC-157 Stocked locally | Rat tendon and ligament healing studies; no published human trials |
| Sleep | DSIP Stocked locally | Small double-blind human insomnia trials from the 1980s and 1990s, with mixed results |
| Hair growth | GHK-Cu (topical) Stocked locally | Hair and follicle effects listed in a review of cell and animal work; no human hair trial found |
| Skin | Argireline | A small randomised, placebo-controlled human trial on expression lines |
Injury and tissue healing
BPC-157 is the compound most associated with injury recovery on the research-peptide market, and it also has the deepest published research trail of the three compounds usually sold for this purpose. That research is rat and cell work on tendon, ligament and gut healing from a Croatian laboratory; no controlled human trial has been published. TB-500, a synthetic fragment of thymosin beta-4, has a smaller and more recent animal literature, including a 2026 rat study that compared it directly with BPC-157. GHK-Cu, sold as an injectable vial for this purpose, has animal wound-healing data but no human injection trials at all. The full breakdown, including what each study actually measured, is in best peptides for injury healing.
Sleep
DSIP, delta sleep-inducing peptide, was isolated from the blood of sleeping rabbits in 1977 and named for its apparent link to deep-sleep brain waves. Small double-blind human trials followed in the 1980s and early 1990s; one reported clear benefit, a later and larger one found only weak effects and concluded DSIP was unlikely to be of major benefit for chronic insomnia. No trial has tested it since. MK-677, a growth hormone secretagogue rather than a peptide, produced more deep sleep and REM sleep in a small 1997 study, a secondary finding rather than its intended use. Epitalon has a following in longevity circles for pineal and circadian effects, but the human data on this specific point is thin and uncontrolled. See best peptides for sleep for the studies behind each.
Hair growth
This is the thinnest category on the site. The only compound in this library with any published link to hair growth is GHK-Cu: a 2018 review by the peptide's discoverer lists increased hair growth and follicle size among its effects in cell and animal work, but describes no human hair trial. That applies to the topical form; the injectable version sold for the same purpose has even less behind it, since it lacks the topical form's small human skin studies too. The GLOW blend, marketed partly on a hair claim, has never been studied as a combination. Full detail is in best peptides for hair growth.
Skin
Argireline, a six-amino-acid mimic of part of the SNAP-25 protein, is the only compound in this group with a small randomised, placebo-controlled human trial behind it, run in 60 Chinese adults with lines around the eyes in 2013. GHK-Cu (topical) has a broader set of small human cosmetic studies, 8 to 12 weeks each, on skin density, firmness and fine lines, though none was a large placebo-controlled trial. SNAP-8, argireline's eight-amino-acid cousin, has no peer-reviewed human trial that could be found; the efficacy figures sold with it trace back to manufacturer material. Injectable GHK-Cu, despite sharing a category with the topical form, has only cell and animal evidence for the injected route. The comparisons are in best peptides for skin.
Reading the evidence tiers correctly
"Animal only" does not mean worthless, and "small human trial" does not mean settled. A rat tendon study can point researchers toward a mechanism worth testing in people; it just has not been tested in people yet. A 60-person placebo-controlled trial is real human evidence, but it is not the same as the large, multi-year trials behind an approved drug like semaglutide or tirzepatide. Each goal guide states which tier applies so that a marketing description like "clinically studied" or "research-backed" can be checked against what was actually done, in what species, with how many people.
What this hub does not cover yet
These four guides do not cover every goal peptides are sold for in the Philippines, such as fat loss, muscle growth, gut health or general longevity. Those questions are answered on the individual compound pages in the meantime; browse the full list at /peptides.
